Clinical trial · Observational
Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular Carcinoma
NCT05575622CI-TRIAL-00061627unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project intends to perform CTC PD-L1 imaging, exosomal PD-L1 protein detection, and exosomal LAG-3 protein detection, so as to resolve the functional marker profiles of immunotherapy in the peripheral blood of HCC patients and comprehensively present the responsiveness of patients to immunotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with hepatocellular carcinoma receiving immunotherapy
- interventionNames
- Device: CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection
Primary outcomes (1)
- measure
- CTC-PD-L1, exosomal PD-L1, and exosomal LAG-3
- timeFrame
- Treatment baseline; Up to 2 months from the initial treatment; From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * having signed informed consent * clinically or pathologically confirmed hepatocellular carcinoma; * liver tumor load not exceeding 50% of liver volume; * expected survival ≥ 12 weeks; * vital organ function meeting enrollment criteria; and (6) no need for pregnancy. Exclusion Criteria: * Patients who have been diagnosed with malignant tumors of other systems or organs; * Patients with hematologic disorders and extreme physical failure; * Patients with immune deficiencies or organ transplants; * Other conditions deemed by the investigator to be inappropriate for participation in this study.
References
Publications (0)
Data not yet available
No reference posted for this study.